Mkts

Theravance Biopharma, Inc.

NASDAQ: TBPH
$0.00+0.00 (+0.00%)
As of Dec 31, 7:00 PM ET

Key statistics

52-week range
13.0821.03
Today
Open0.00
Previous close0.00
Volume0
Valuation
Market cap884.18M
P/E ratio16.43×
EPS (TTM)1.01
Income & risk
Dividend / yield—
Beta-0.19
Avg volume743.0K
Discussion

TBPH News

Stories mentioning TBPH from around the web — every one is an open thread, so give it a like or add your take.

All news →

Loading news…

Financial statements

Financial statements

As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.

Line itemQ1 '26Mar 31Q4 '25Dec 31Q3 '25Sep 30Q2 '25Jun 30Q1 '25Mar 31Q4 '24Dec 31Q3 '24Sep 30Q2 '24Jun 30
Income Statement
Revenue17,69945,89119,99026,19515,38818,75416,86814,256
Cost of Goods Sold
Gross Profit
Operating Expenses
Research & Development5,8297,3608,11210,49011,4529,4539,2689,954
Sales General & Admin17,72018,51918,33318,43018,37018,50116,87517,056
Total Operating Expenses27,18225,87926,44528,92029,82227,95427,70529,961
Operating Income (Loss)(9,483)20,012(6,455)(2,725)(14,434)(9,200)(10,837)(15,705)
Interest Income
Interest Expense
Other Expense3,0133,6384,1391,457939.00904.001,4151,128
Pretax Income(6,470)73,068(2,889)73,206(14,138)(8,939)(10,052)(15,221)
Tax Provision(1,537)12,044(6,504)18,371(559.00)6,5882,6461,308
Net Income (Loss)(4,933)61,0243,61554,835(13,579)(15,527)(12,698)(16,529)
Earnings Per Share (Basic)(0.10)1.200.071.09(0.27)(0.31)(0.26)(0.34)
Earnings Per Share (Diluted)(0.10)1.150.071.08(0.27)(0.31)(0.26)(0.34)
Weighted Average Shares Outstanding (Basic)51,27950,31750,52050,17749,70648,84749,03848,747
Weighted Average Shares Outstanding (Diluted)51,27951,50751,90850,72649,70648,84749,03848,747

Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.

Key facts

About TBPH

Theravance Biopharma, Inc. (NASDAQ: TBPH) is a stock listed on the Nasdaq Stock Market under the ticker symbol TBPH. It last traded at $0.0000 (Dec 31, 1969, 7:00 PM ET), unchanged on the day. That gives Theravance Biopharma a market capitalisation of $884.2M and a price-to-earnings ratio of 16.4.

Over the past 52 weeks TBPH has traded between $13.08 and $21.03.

Revenue for the quarter ended Mar 31, 2026 was $17.7M; a net loss of $4.9M. Revenue was up 15.0% from $15.4M in the quarter ended Mar 31, 2025.

Last 4 quarters
Quarter endedRevenueNet incomeMargin
Mar 31, 2026$17.7M-$4.9M-27.9%
Dec 31, 2025$45.9M$61.0M133.0%
Sep 30, 2025$20.0M$3.6M18.1%
Jun 30, 2025$26.2M$54.8M209.3%

From Theravance Biopharma’s quarterly (10-Q) filings, in US dollars.

Latest News

Market news from around the web — every story is an open thread, so give it a like or add your take.

All news →

Loading news…